Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders.
The clinically tested reversible inhibitors of monoamine oxidase A (RIMAs) include brofaromine, moclobemide and toloxatone. Moclobemide has shown unequivocal antidepressant activity against serious depressive illness in 4 placebo-controlled double-blind trials. It has been compared with amitriptyline, imipramine, clomipramine, desipramine, maprotiline, fluoxetine, fluvoxamine, tranylcypromine, toloxatone, mianserin and amineptine in the treatment of depressive disorders. Meta-analysis showed convincing evidence of moclobemide efficacy, comparable with the most potent antidepressants available. The efficacy of moclobemide has been demonstrated in psychotic and non-psychotic depression, in depression with and without melancholia, in endogenous depression (both unipolar and bipolar), in retarded depression and in agitated depression. The efficacy of moclobemide, allied to the unusually benign side effect profile, has led to exploration of its use in other disorders. Two small studies have given encouraging results in the treatment of attention-deficit hyperactivity disorder. Large placebo-controlled studies have shown the activity of moclobemide in the depression that accompanies dementia (such as senile dementia of Alzheimer type). The results also suggested that, in this patient population, cognitive ability improved in parallel. Social phobia has also been shown to improve on treatment with either moclobemide or brofaromine. Clinical trials are in progress on the effect of moclobemide in chronic fatigue syndrome. Moreover, there are encouraging results with the use of brofaromine and moclobemide in panic disorder. Other disorders in which treatment with RIMA is of interest include agoraphobia, bulimia, borderline personality disorder, post-traumatic stress disorder, compulsive hair pulling (trichotillomania), dysmorphophobia, kleptomania as well as various anxiety syndromes.
Priest
R G
RG
Department of Psychiatry, St Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, University of London, United Kingdom.
Gimbrett
R
R
Roberts
M
M
Steinert
J
J
D000544:Alzheimer Disease / Q000188:drug therapy*; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D001549:Benzamides / Q000627:therapeutic use; D006801:Humans; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010080:Oxazoles / Q000627:therapeutic use; D023303:Oxazolidinones; D016584:Panic Disorder / Q000188:drug therapy*; D010698:Phobic Disorders / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use
D000929:Antidepressive Agents, Tricyclic; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D010080:Oxazoles; D023303:Oxazolidinones; D010880:Piperidines; C010798:toloxatone; C038213:brofaromine; D020912:Moclobemide; C026234:cimoxatone